Loading organizations...
§ Private Profile · Princeton, NJ, USA
Biotechnology R&D company advancing drug candidates via medicinal chemistry for cardiovascular, renal, and infectious diseases.
KBP Biosciences, founded in 2011 by Dr. Huang Zhenhua who holds a 40% ownership stake, is a biotechnology R&D company focused on innovative therapies for hypertension, heart and kidney disease, and infectious diseases. The firm leverages a medicinal chemistry platform to advance drug candidates like KBP-5074, a mineralocorticoid receptor antagonist for cardiovascular disease. Its global headquarters are in Singapore, with operations also spanning China and the United States. Notable past leadership includes former CEO Brian McVeigh, who previously held roles at GlaxoSmithKline. KBP Biosciences has successfully raised $76 million in Series A financing and reported holding $218 million in a bank account as of December 31, 2023. Its business model centers on private biotech firm funded through venture financing, such as a $76 million Series A round.
KBP Biosciences has raised $76.0M across 1 funding round.
KBP Biosciences has raised $76.0M in total across 1 funding round.
KBP Biosciences has raised $76.0M in total across 1 funding round.
KBP Biosciences's investors include Benjamin Qiu, Jianping Tang, Fred Craves, Cash Capital, Efung Capital, Elite Capital, GF Xinde Life Science Investment Fund, Korea Investment Partners, Ping An Ventures, Sangel Capital.
KBP Biosciences has raised $76.0M across 1 funding round. Most recently, it raised $76.0M Series A in January 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 5, 2018 | $76M Series A | Benjamin QIU, Jianping Tang | Fred Craves, Cash Capital, Efung Capital, Elite Capital, GF Xinde Life Science Investment Fund, Korea Investment Partners, Ping AN Ventures, Sangel Capital | Announced |